Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2026)
Caribou Biosciences (CRBU) reported EBITDA Margin of 1051.77% for Q1 2026, up 65154.0% year-over-year from N/an in Q1 2025, and down 56.55% on a QoQ basis from 671.86% in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of EBITDA Margin data on file, last reported at 1051.77% in Q1 2026.
- Quarterly EBITDA Margin rose 65154.0% year-over-year to 1051.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1190.83% (up 29508.0% YoY) and the FY2025 annual result came in at 1328.77%, up 16093.0% from the prior year.
- EBITDA Margin declined to 1051.77% in Q1 2026 per CRBU's latest filing, from 671.86% in the prior quarter.
- Across five years, EBITDA Margin topped out at 41.62% in Q3 2023 and bottomed at 2033.18% in Q2 2025.
- The 5-year median for EBITDA Margin is 941.37% (2023), against an average of 1082.43%.
- The widest annual swing landed in 2024, when EBITDA Margin sank 161728 bps; it then jumped 106256 bps in 2025.
- Tracing CRBU's EBITDA Margin over 5 years: stood at 717.01% in 2022, then plunged by 31 bps to 941.37% in 2023, then sank by 84 bps to 1734.42% in 2024, then jumped by 61 bps to 671.86% in 2025, then tumbled by 57 bps to 1051.77% in 2026.
- Per Business Quant, the three latest CRBU EBITDA Margin figures stand at 1051.77% (Q1 2026), 671.86% (Q4 2025), and 1250.91% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -1,051.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,051.77% |
| Dec 31, 2025 | -671.86% |
| Sep 30, 2025 | -1,250.91% |
| Jun 30, 2025 | -2,033.18% |
| Mar 31, 2025 | -1,703.31% |
| Dec 31, 2024 | -1,734.42% |
| Sep 30, 2024 | -1,658.89% |
| Jun 30, 2024 | -1,088.16% |
| Mar 31, 2024 | -1,712.06% |
| Dec 31, 2023 | -941.37% |
| Sep 30, 2023 | -41.62% |
| Jun 30, 2023 | -796.94% |
| Mar 31, 2023 | -778.30% |
| Dec 31, 2022 | -717.01% |
| Sep 30, 2022 | -820.50% |
| Jun 30, 2022 | -648.59% |
| Mar 31, 2022 | -752.33% |
| Dec 31, 2021 | -727.39% |
| Sep 30, 2021 | -527.38% |
| Jun 30, 2021 | -969.58% |
| Mar 31, 2021 | -829.70% |
| Dec 31, 2020 | -1,545.83% |
| Sep 30, 2020 | -686.89% |
| Jun 30, 2020 | -26.60% |
| Mar 31, 2020 | -613.11% |